Chapter: Medicine and surgery: Haematology and clinical Immunology

Multiple myeloma - Paraproteinaemias

Multiple myeloma is a malignant clonal proliferation of plasma cells. - Definition, Incidence, Aetiology, Pathophysiology, Clinical features, Complications, Investigations, Management, Prognosis.

Paraproteinaemias

 

Multiple myeloma

 

Definition

 

Multiple myeloma is a malignant clonal proliferation of plasma cells.

 

Incidence

 

3 per 100,000.

 

Age

 

Most commonly diagnosed 60–65 years.

 

Sex

 

2M : 1F

 

Pathophysiology

 

There is expansion of a single clone of plasma cells that replace normal bone marrow and produce monoclonal immunoglobulins. Cleavage of these immunoglobulins result in the production of Fab and Fc fragments; the Fab fragment is termed the Bence-Jones protein and is found in the urine of patients with myeloma. If the antibody polymerises there may be hyperviscosity of the blood. There is also production of osteoclast stimulation factor causing lytic bone lesions, bone pain and hypercal-caemia. Incomplete immunoglobulins may precipitate in the tissues as amyloid. Renal damage may result from deposition of light chains, amyloid or hypercalcaemia.

 

Clinical features

 

Marrow infiltration results in anaemia, thrombocy-topenia and leucopenia.

 

Lytic bone lesions most commonly in the axial skeleton may result in pathological fractures and bone pain. Spinal cord compression occurs in approximately 10–20% of patients at some time during the course of disease. Hypercalcaemia causes thirst, polyuria, constipation and abdominal pain.

Renal failure.

 

Investigations

 

The diagnosis of myeloma is made if there are:

 

·        Bone marrow aspirate has at least 10–15% plasma cells.

 

·        Lytic lesions on skeletal survey.

 

·        Monoclonal immunoglobulins in the urine or blood. Other investigations include:

 

·        FBC may show signs of marrow infiltration anaemia, thrombocytopenia, leucopenia.

 

·        The ESR is raised if there is a serum paraprotein. Serum calcium may be raised.

 

·        Hyperuricemia due to increased cell turnover.

 

Management

 

Chemotherapy with single alkylating agents improves prognosis. High dose combination chemotherapy with or without haemapoetic progenitor cell transplantation is used in younger patients. Recently, thalidomide has been demonstrated to produce a significant response in 30% of patients whose disease progressed following other therapy. Supportive care includes blood transfusion, radiotherapy for localised bone pain, correction of hypercalcaemia with bisphosphonates and management of renal impairment.

Study Material, Lecturing Notes, Assignment, Reference, Wiki description explanation, brief detail
Medicine and surgery: Haematology and clinical Immunology : Multiple myeloma - Paraproteinaemias |


Privacy Policy, Terms and Conditions, DMCA Policy and Compliant

Copyright © 2018-2023 BrainKart.com; All Rights Reserved. Developed by Therithal info, Chennai.